Winson S. Ho
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Winson S. Ho is an Assistant Professor at the University of California. His research primarily focuses on the treatment of pediatric brain tumors, particularly through innovative therapies such as laser interstitial thermal therapy. He has published extensively on topics related to glioma-immune cell interactions and the effects of neoadjuvant chemotherapy in central nervous system neuroblastoma. His work contributes to advancing our understanding of tumor progression and enhancing antitumor immunity against glioblastoma.
Articles (7)
Year:
2026
Laser interstitial thermal therapy (LITT) has emerged as a minimally invasive neurosurgical technique for achieving precise, MR-guided thermal ablation of intracranial lesions. LITT offers a viable alternative for lesions that are deep-seated or located in eloquent regions where conventional surgery poses significant risk. In adult neuro-oncology, LITT is well-established, particularly for recurrent high-grade gliomas and post-radiation metastases. In pediatric neuro-oncology, LITT has been most widely adopted for treating hypothalamic hamartomas, where it achieves high rates of seizure freedom with minimal morbidity. However, its use for oncologic control in pediatric brain tumors remains limited, with published evidence confined to retrospective series with heterogeneous tumor types. Recent studies suggest potential for LITT not only in cytoreduction but also in enhancing drug delivery via transient blood-brain barrier disruption and in promoting antitumor immunity through hyperthermia-induced immunogenic cell death. We review the principles, clinical applications, and imaging features of LITT, with a focus on pediatric brain tumors. Illustrative cases are presented, and the need for prospective, multi-center trials is emphasized to better define LITT’s therapeutic role and optimize its integration with emerging chemo- and immunotherapy strategies.
Year:
2025
Glioma progression is a complex process controlled by molecular factors that coordinate the crosstalk between tumor cells and components of the tumor microenvironment (TME). Among these, immune cells play a critical role in cancer survival and progression. The complex interplay between cancer cells and the immune TME influences the outcome of immunotherapy and other anti-cancer therapies. Here, we present an updated view of the pro- and anti-tumor activities of the main myeloid and lymphocyte cell populations in the glioma TME. We review the underlying mechanisms involved in crosstalk between cancer cells and immune cells that enable gliomas to evade the immune system and co-opt these cells for tumor growth. Lastly, we discuss the current and experimental therapeutic options being developed to revert the immunosuppressive activity of the glioma TME. Knowledge of the complex interplay that elapses between tumor and immune cells may help develop new combination treatments able to overcome tumor immune evasion mechanisms and enhance response to immunotherapies.
Year:
2024
Glioblastoma (GBM) is an immunologically “cold” tumor that does not respond to current immunotherapy. Here, we demonstrate a fundamental role for the α-isoform of the catalytic subunit of protein phosphatase-2A (PP2Ac) in regulating glioma immunogenicity. Genetic ablation of PP2Ac in glioma cells enhanced double stranded DNA (dsDNA) production and cGAS-type I interferon (IFN) signaling, MHC-I expression, and tumor mutational burden. In co-culture experiments, PP2Ac deficiency in glioma cells promoted dendritic cell (DC) cross presentation and clonal expansion of CD8+ T cells. In vivo, PP2Ac depletion sensitized tumors to immune checkpoint blockade and radiotherapy treatment. Single cell analysis demonstrated that PP2Ac deficiency increased CD8+ T cell, NK cell, and DC accumulation and reduced immunosuppressive tumor associated macrophages. Furthermore, loss of PP2Ac increased IFN signaling in myeloid and tumor cells and reduced expression of a tumor gene signature associated with worse patient survival in TCGA. Collectively, this study establishes a novel role for PP2Ac in inhibiting dsDNA-cGAS-STING signaling to suppress anti-tumor immunity in glioma.
Year:
2024
Glioblastoma (GBM) is an immunologically “cold” tumor that does not respond to current immunotherapy. Here, we demonstrate a fundamental role for the α-isoform of the catalytic subunit of protein phosphatase-2A (PP2Ac) in regulating glioma immunogenicity. Genetic ablation of PP2Ac in glioma cells enhanced double-stranded DNA (dsDNA) production and cGAS–type I IFN signaling, MHC-I expression, and tumor mutational burden. In coculture experiments, PP2Ac deficiency in glioma cells promoted dendritic cell (DC) cross-presentation and clonal expansion of CD8+ T cells. In vivo, PP2Ac depletion sensitized tumors to immune-checkpoint blockade and radiotherapy treatment. Single-cell analysis demonstrated that PP2Ac deficiency increased CD8+ T-cell, natural killer cell, and DC accumulation and reduced immunosuppressive tumor-associated macrophages. Furthermore, loss of PP2Ac increased IFN signaling in myeloid and tumor cells and reduced expression of a tumor gene signature associated with worse patient survival in The Cancer Genome Atlas. Collectively, this study establishes a novel role for PP2Ac in inhibiting dsDNA–cGAS–STING signaling to suppress antitumor immunity in glioma. Significance: PP2Ac deficiency promotes cGAS–STING signaling in glioma to induce a tumor-suppressive immune microenvironment, highlighting PP2Ac as a potential therapeutic target to enhance tumor immunogenicity and improve response to immunotherapy.
Year:
2023
Year:
2023
Year:
2020
Collaborators (5)
Aaron Diaz
University of California, San Francisco
Jinan Behnan
Assist.Prof
Karolinska Institutet
Bohyeon Yu
University of California, San Francisco
Beisi Xu
Principal Bioinformatics Research Scientist
St. Jude Children's Research Hospital
Zhipeng Meng
Assistant Professor
University of Miami Miller School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.